PROTXX and University of Alberta Announce Remote Personalized Healthcare Management of Patients With Multiple Sclerosis

Silicon Valley, California and Calgary, Alberta based precision medicine technology pioneer PROTXX and the University of Alberta in Edmonton, Alberta today announced a new research collaboration that will leverage the PROTXX precision healthcare platform for remote personalized health management of patients with multiple sclerosis (MS). The PROTXX precision healthcare platform integrates wearable sensor and machine learning innovations to replace bulky and expensive clinical equipment and time-consuming testing procedures for a variety of neurodegenerative medical conditions in which patients suffer from impairments to multiple physiological systems. PROTXX solves the difficult problem of identifying and quantifying these multiple different impairments, disrupting diagnosis and treatment with easy-to-use, low-cost, precision patient assessments. MS is an autoimmune inflammatory and neurodegenerative disease of the central nervous system (CNS) that causes progressive disability in motor, visual, sensory, autonomic, and cognitive functions. The prevalence of MS in Canada is among the highest reported in the world, affecting over 100,000 Canadians and costing the Canadian healthcare system close to one billion dollars per year. Moreover, MS is on the rise in Canada, predominantly amongst women, and is the leading cause of neurological disability amongst people ages 20-40 years. MS has been dubbed "Canada's disease" by Maclean's (April 27, 2015). The University of Alberta and PROTXX have been awarded a Mitacs Accelerate grant to support post-doctoral research fellows participating in the project in 2020-2021. Project co-leads at the University of Alberta are: